Fundraising FoxHBM Healthcare Investments — 2026 Investments
2 investments dated 2026 · listed companies and verified rows first · show all
Develops therapies for cardiometabolic conditions.
Co-investorsNew Enterprise Associates (NEA)RA CapitalRTW Investments L.P.
Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.
BiotechHealthtechSouth San Francisco, US
Carolyn Bertozzi(Lycia founder and Professor of Chemistry, Stanford University)inAetna Wun Trombley(President and CEO)inAmy Bachrodt(Chief Financial Officer)inChin Lee(Chief Medical Officer)inSteve Staben(Chief Scientific Officer)inSofia Touami(Chief Business Officer)in
Co-investorsREDMILEVersant VenturesHBM PartnersBAM ElevateFranklin TempletonInvus+5 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.